- Home
- REFR vs IMA Comparison
REFR vs IMA Comparison
Compare REFR & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | REFR | IMA |
|---|---|---|
| Founded | 1965 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.8M | 65.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | REFR | IMA |
|---|---|---|
| Price | $1.14 | $7.11 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | ★ 46.1K | 36.9K |
| Earning Date | 03-05-2026 | 03-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,227,276.00 | $800,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.93 | $5.70 |
| 52 Week High | $2.70 | $18.00 |
Technical Indicators
Market Signals| Indicator | REFR | IMA |
|---|---|---|
| Relative Strength Index (RSI) | 32.42 | 52.81 |
| Support Level | $1.14 | $6.92 |
| Resistance Level | $1.32 | $7.60 |
| Average True Range (ATR) | 0.08 | 0.44 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 10.49 | 69.18 |
Price Performance
Historical ComparisonAbout REFR Research Frontiers Incorporated
Research Frontiers Inc is engaged in the development and marketing of technology and devices to control the flow of light. The company develops and licenses its patented suspended particle device light-control technology to other companies that manufacture and market the SPD-Smart chemical emulsion, the light-control film made from the chemical emulsion, the light-control panels made by laminating the film, electronics to power end-products incorporating the film, or lamination services for, and the end-products. The company's revenue source comes from the licensing of technology.
About IMA ImageneBio Inc.
ImageneBio Inc is a clinical-stage biopharmaceutical company that develops differentiated therapies for immunological and inflammatory (I&I) diseases. The company is focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody, for the treatment of atopic dermatitis.